GLP-1 Prescriptions for Teens: Age 12+ Rules and Who Can Prescribe

Yes, a 12- to 17-year-old can be prescribed a GLP-1 for obesity, but only a few products carry adolescent labeling: Wegovy injection and liraglutide 3 mg (Saxenda and its generics). Zepbound, Foundayo, and the Wegovy pill are labeled for adults only. In practice, a teen's prescription usually comes from a pediatrician or pediatric obesity program with a parent or guardian involved, and coverage runs through the family's plan or Medicaid.

Which drugs are labeled for teens

FDA labeling decides what a prescriber can point to as studied and approved in adolescents, and it also shapes what insurers will cover.

Source: Wegovy PI (rev. 06/2026); Saxenda PI (rev. 02/2026); Qsymia PI (rev. 03/2026); Wegovy tablets PI (rev. 06/2026); Zepbound PI (rev. 08/2026); Foundayo PI (rev. 07/2026); Lomaira label on DailyMed.

Generic liraglutide 3 mg, the Saxenda equivalent, has been sold in the US since 2025. Note that the brand Saxenda is being discontinued, with last wholesaler shipments in late January 2027, so new teen prescriptions for liraglutide will increasingly be written for generics.

How eligibility is measured in adolescents

Adults qualify by BMI numbers (generally 30 or higher, or 27 or higher with a related condition). Teens are measured against growth charts instead. The AAP clinical practice guideline defines obesity as "a BMI at or above the 95th percentile for children and teens of the same age and sex," and severe obesity as at or above 120% of the 95th percentile.

The labels reflect this. Wegovy's pediatric weight-reduction use is based on a trial in adolescents with a BMI at or above the 95th percentile for age and sex. Liraglutide uses a weight floor (above 60 kg) and a BMI equivalent to an adult BMI of 30.

Insurers build PA criteria on the same definitions. Cigna's weight-loss GLP-1 criteria (revised April 2026) require patients 12 to 17 to have a baseline BMI at or above the 95th percentile and 3 months of behavioral modification and dietary restriction, and they apply pediatric criteria only to liraglutide and Wegovy injection. Renewal for teens requires a BMI reduction of at least 1% from baseline.

What the AAP guideline says

The AAP published its first comprehensive obesity guideline for children and adolescents on January 9, 2023. As HealthDay reported, it states that "adolescents aged 12 years and older with obesity should be offered weight loss pharmacotherapy," combined with health behavior and lifestyle treatment, and that adolescents 13 and older with severe obesity should be referred for evaluation for metabolic and bariatric surgery.

The guideline describes intensive health behavior and lifestyle treatment as foundational, most effective when it is face-to-face, engages the whole family, and delivers at least 26 hours of contact over 3 to 12 months. Expect a pediatric prescriber to pair any medication with this kind of program, and to document it, since insurers often ask.

Affiliate disclosure: this site may earn a commission if you use links in boxes like the one above. It does not affect what this guide says.

Who can prescribe, and why online options are limited

Any licensed prescriber can legally write an FDA-approved drug for a minor within their scope of practice, but teens typically start through one of these routes:

1. The pediatrician or family doctor. They have the growth-chart history and can coordinate lifestyle treatment.
2. A pediatric weight-management or endocrinology program. Often the best fit for severe obesity, other conditions such as prediabetes, or when surgery may be considered.
3. Telehealth. Don't assume a direct-to-consumer weight-loss service treats minors; check its age policy first. If one does see adolescents, confirm in writing how parental consent works and how it coordinates with your child's primary care doctor.

Parental consent

In most situations a parent or legal guardian consents to a minor's treatment, and state law sets the exceptions. Expect the prescriber to want a parent present for the initial visit and involved in follow-up, because adolescent dosing can escalate more slowly and needs monitoring.

Monitoring built into the labels

• Liraglutide: dose escalation in adolescents "may take up to 8 weeks," and the label says to evaluate after 12 weeks on the maintenance dose and discontinue if BMI has not dropped by at least 1%.
• Wegovy injection: pediatric maintenance is 2.4 mg weekly, or 1.7 mg if needed. The higher 7.2 mg adult option is not established for pediatric patients.
• Qsymia: pediatric patients are assessed by BMI reduction, and the label recommends pregnancy testing before and monthly during treatment for patients who can become pregnant.

Coverage: parents' plans and Medicaid

Commercial plans

A teen on a parent's employer or marketplace plan is subject to that plan's weight-management rules. Some plans exclude weight-loss drugs for all ages; others cover them with PA. Check the formulary for Wegovy and liraglutide specifically, since those are the products with adolescent labeling.

Medicaid and EPSDT

For children and teens on Medicaid, the Early and Periodic Screening, Diagnostic and Treatment benefit is the key rule. Medicaid.gov explains that EPSDT covers enrollees under 21 and that states must provide federally coverable, medically necessary services to treat or improve a condition "regardless of whether the service is covered in a state's Medicaid plan."

That matters when a state cuts weight-loss drug coverage. A May 2026 MassHealth bulletin ended coverage of Wegovy and similar drugs for obesity alone as of July 3, 2026, but lists "members younger than 21 when medically necessary under EPSDT" among the indications that remain coverable. Other states' Medicaid programs set their own PA processes, so ask your child's prescriber to submit the request with EPSDT medical-necessity documentation.

Questions worth asking the prescriber

• Which labeled option fits my child's weight, age, and other conditions, and why that one?
• What is the escalation plan, and what happens if a dose increase isn't tolerated?
• When will you check whether the medication is working, and what result would lead you to stop it?
• Who handles the prior authorization, and what documentation will you include?
• How will the lifestyle part of treatment be delivered and documented alongside the prescription?

Clear answers to these questions make renewals easier later, because insurers commonly ask for proof of response and ongoing lifestyle treatment when an initial approval runs out.

A parent's checklist before the appointment

1. Bring your child's growth-chart BMI history or ask the office to print it.
2. List current medications and diagnoses (including prediabetes, sleep apnea, or high blood pressure).
3. Note any lifestyle programs your family has done, with dates.
4. Check your plan's formulary for Wegovy and liraglutide and whether PA is required.
5. If your child is on Medicaid, ask the office to cite EPSDT medical necessity in the request.
6. Ask what the follow-up schedule will be and who to contact about side effects.

Affiliate disclosure: this site may earn a commission if you use links in boxes like the one above. It does not affect what this guide says.

Sources

1. Wegovy (semaglutide) prescribing information, Novo Nordisk (rev. 06/2026)
2. Saxenda (liraglutide) prescribing information, Novo Nordisk (rev. 02/2026)
3. Qsymia (phentermine and topiramate) prescribing information, FDA (rev. 03/2026)
4. Wegovy (semaglutide) tablets prescribing information, FDA (rev. 06/2026)
5. Zepbound (tirzepatide) prescribing information, Eli Lilly (rev. 08/2026)
6. Foundayo (orforglipron) prescribing information, Eli Lilly (rev. 07/2026)
7. Lomaira (phentermine) label, DailyMed
8. NovoCare: Saxenda (discontinuation notice)
9. Healio: FDA approves first generic GLP-1 indicated for weight loss
10. Hampl SE et al. AAP Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics 2023;151(2):e2022060640
11. HealthDay: AAP issues guidelines for children with overweight, obesity (Jan. 10, 2023)
12. Cigna: Weight Loss GLP-1 Agonists prior authorization criteria (rev. 04/15/2026)
13. Medicaid.gov: Early and Periodic Screening, Diagnostic, and Treatment
14. MassHealth Pharmacy Facts No. 276 (May 13, 2026, corrected)

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.